|
Bladder cancer is one of the most expensive cancers to manage due to frequent recurrences requiring life-long
surveillance and treatment. A near-infrared labeled 2-deoxy-d-glucose probe IRDye800CW-DG targeting glucose
metabolism pathway has shown to enhance the sensitivity of diagnosing several types of cancers as tested on tumor
models not including bladder tumor. This pilot study has explored differential uptake of intravesically administered
IRDye800CW-DG in an orthotopic rat bladder tumor model. Twenty-five female Fischer rats were randomly
grouped to four conditions: no-tumor-control (n=3), no-tumor-control intravesically instilled with IRDye800CWDG
(n=6), rats bearing GFP-labeled AY-27 rat bladder urothelial cell carcinoma cells and washed with saline (n=5),
and rats bearing AY-27 tumors and intravesically instilled with IRDye800CW-DG (n=11). Near-infrared
fluorescence was measured from the opened bladder wall of anesthetized rat at an excitation wavelength of 750nm
and an emission wavelength of 776nm, by using an in-house fluorescence imaging system. There is no statistically
significant difference of the peak fluorescence intensity among the no-tumor-control bladders (n=3), the no-tumorcontrol
bladders instilled with IRDye800CW-DG (n=6), and the GFP-labeled AY-27 treated bladders washed by
saline (n=5). When compared to that of the no-tumor-control bladders instilled with IRDye800CW-DG (n=6), the
fluorescence intensity of GFP-labeled AY-27 treated bladders instilled with IRDye800CW-DG and with histology
confirmed neoplastic bladder tissue (n=11) was remarkably more intense (3.34 fold of over the former) and was also
statistically significant (p<0.0001). The differential uptake of IRDye800CW-DG by the neoplastic urinary bladder
tissues suggests the potential for cystoscopy-adaptation to enhance diagnosis and guiding surgical management of
flat urinary bladder cancer.
|
